Valneva SE ADR is a biotechnology firm headquartered in Saint-Herblain, France, dedicated to the research, development, and commercialization of innovative vaccines targeting urgent unmet medical needs in infectious diseases. The company boasts a promising pipeline that includes candidates for Lyme disease and chikungunya, showcasing its commitment to addressing significant health challenges through advanced scientific solutions. With the global demand for effective vaccination strategies on the rise, Valneva's focus on developing unique vaccine products positions it favorably within the healthcare sector, making it an appealing investment opportunity for institutional investors interested in growth within the biotech landscape. Show more

Location: 6 RUE ALAIN BOMBARD, SAINT-HERBLAIN, FRANCE, 44800, Saint-Herblain, 44800, USA | Website: https://valneva.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

798.6M

52 Wk Range

$5.43 - $12.25

Previous Close

$9.21

Open

$9.17

Volume

6,098

Day Range

$9.07 - $9.19

Enterprise Value

891.4M

Cash

143.5M

Avg Qtr Burn

-17.44M

Insider Ownership

0.00%

Institutional Own.

6.15%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IXCHIQ (VLA1553) Details Chikungunya, Infectious disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VLA15 Details Lyme disease, Bacterial infection	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IXCHIQ (VLA1553) Details Chikungunya, Viral infection	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IXCHIQ (VLA1553) Details Chikungunya, Viral infection	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Shigella4V2 (S4V2) Details Shigella, Nasolabial fold lines	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VLA1601 Details Viral infection, Zika virus	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VLA2001 Details Infectious disease, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.